Literature DB >> 23504701

Lethal neuroleptic malignant syndrome due to amisulpride.

Frank Musshoff1, Elke Doberentz, Burkhard Madea.   

Abstract

A 42-year old-man was found lying in his bed having seizures. Later he became unconscious and hypotonic developing mydriasis as well as rigidity. The body core temperature (rectal temperature) was above 42 °C. Blood pH was decreased during treatment, and his general condition deteriorated. The patient developed gasping respiration, ventricular fibrillation, and died. During autopsy and histological investigation cerebral and pulmonary edema were noted together with general congestion of the internal organs. Further observations included contraction bands of myocytes, a contracted spleen, fibrosis of the liver, and gall stones. Toxicological analyses of peripheral blood revealed the following results: amisulpride 4.65 mg/l, biperiden 0.12 mg/l, imipramine 0.33 mg/l, and desipramine 0.68 mg/l. An amisulpride-induced neuroleptic malignant syndrome was therefore diagnosed as the patho-physiological mechanism leading to death.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23504701     DOI: 10.1007/s12024-013-9410-1

Source DB:  PubMed          Journal:  Forensic Sci Med Pathol        ISSN: 1547-769X            Impact factor:   2.007


  19 in total

1.  [Intoxication with amisulpride (Solian): a case with toxicologic documentations].

Authors:  R Dorne; C Pommier; M Manchon; C Berny
Journal:  Therapie       Date:  2000 Mar-Apr       Impact factor: 2.070

2.  Rhabdomyolysis and coma associated with amisulpride: a probable atypical presentation of neuroleptic malignant syndrome.

Authors:  E Cem Atbasoglu; Halise Devrimci Ozguven; Meram Can Saka; Ceren Goker
Journal:  J Clin Psychiatry       Date:  2004-12       Impact factor: 4.384

3.  Neuroleptic malignant syndrome due to amisulpride in a patient with solvent-induced chronic toxic encephalopathy.

Authors:  Vaios Peritogiannis; Sofia Tsouli; Dimitrios Pappas; Venetsanos Mavreas; Spiros Konitsiotis
Journal:  Clin Neuropharmacol       Date:  2007 Jul-Aug       Impact factor: 1.592

4.  Amisulpride-induced neuroleptic malignant syndrome.

Authors:  Ercan Abay; Rugul Kose
Journal:  J Neuropsychiatry Clin Neurosci       Date:  2007       Impact factor: 2.198

5.  The spectrum concept and prevalence of neuroleptic malignant syndrome.

Authors: 
Journal:  Am J Psychiatry       Date:  1988-08       Impact factor: 18.112

Review 6.  Neuroleptic malignant syndrome.

Authors:  J L Levenson
Journal:  Am J Psychiatry       Date:  1985-10       Impact factor: 18.112

7.  Amisulpride and neuroleptic malignant syndrome.

Authors:  Ming-Che Tu; Cheng-Cheng Hsiao
Journal:  Chang Gung Med J       Date:  2011 Sep-Oct

8.  [Malignant neuroleptic syndrome associated with amisulpride].

Authors:  C Harter; C Obier; K-F Druschky; B Eikelmann
Journal:  Nervenarzt       Date:  2008-01       Impact factor: 1.214

Review 9.  Neuroleptic malignant syndrome associated with atypical antipsychotic drugs.

Authors:  Julian N Trollor; Xiaohua Chen; Perminder S Sachdev
Journal:  CNS Drugs       Date:  2009       Impact factor: 5.749

10.  Amisulpride poisoning: a report on two cases.

Authors:  A Tracqui; C Mutter-Schmidt; P Kintz; C Berton; P Mangin
Journal:  Hum Exp Toxicol       Date:  1995-03       Impact factor: 2.903

View more
  2 in total

Review 1.  [Pharmacotherapy of psychiatric acute and emergency situations: General principles].

Authors:  T Messer; F-G Pajonk; M J Müller
Journal:  Nervenarzt       Date:  2015-09       Impact factor: 1.214

2.  Drug information update. Atypical antipsychotics and neuroleptic malignant syndrome: nuances and pragmatics of the association.

Authors:  Siddharth Sarkar; Nitin Gupta
Journal:  BJPsych Bull       Date:  2017-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.